[Reporter's View] The dark side of improved diabetes med convenience

"I lost OOkg with Wegovy," "My appetite completely vanished after taking Munjaro."

Personal stories about obesity treatments are now easily seen on social media platforms like YouTube. Content detailing how much weight was lost, what the side effects were like, and which drugs are more effective is being consumed just like any other everyday lifestyle content.

Most experts emphasize that obesity is not a simple issue of body shape but a chronic disease that requires medical treatment. In reality, obesity is linked to various metabolic disorders such as diabetes, cardiovascular disease, and fatty liver, necessitating a therapeutic approach that considers Body Mass Index (BMI) and the presence of comorbid conditions.

However, the reality is that the perception of obesity treatments is increasingly shifting toward 'weight-loss drugs' rather than treatments for a disease.

The pharmaceutical industry's emphasis on improving medication convenience has also played a significant role in this trend.

The rapid expansion of the GLP-1 class obesity treatment market is due to the convenience of once-weekly administration. Compared to past treatments that required daily oral intake or injections, the burden of use has been significantly lowered, leading to expanded patient access and market growth.

Improvements in medication convenience are evaluated as meaningful changes in terms of patient accessibility and treatment persistence. Indeed, reducing medication burden in chronic disease management improves treatment adherence and patient quality of life. Accordingly, the pharmaceutical industry continues to develop drugs that maintain efficacy for longer periods with fewer administrations.

Currently, the pharmaceutical industry is accelerating the development of various forms of obesity drugs, including oral pills, once-monthly injections, and patches. In a situation where even injections are accepted without much hesitation, the threshold for use is likely to drop even further once new drugs with drastically improved convenience emerge.

The problem is that improved medication convenience does not carry the same meaning as improved medication compliance.

Medication compliance is a concept closer to a patient who consistently maintains therapy according to the proper use and dosage. However, in the current obesity treatment market, 'how easily it can be used' is emphasized first, while discussions on who should use it and how are relatively lacking.

In the online market, health-functional foods and overseas direct-purchase products, some with names similar to those of GLP-1 agents, are spreading rapidly, even though they are unrelated. Some of these products are consumed for weight loss purposes despite lacking sufficient medical validation or safety assessments.

Of course, there is no reason to deny the clinical value of obesity treatments themselves. GLP-1 class treatments are changing the paradigm of obesity management by accumulating diverse data, including reductions in cardiovascular disease risk beyond weight loss. They are undoubtedly an important option for patients who require treatment.

As treatments become more popular, what needs to grow alongside the consumption craze is a clear understanding of medical treatment. As convenience and accessibility increase, social standards regarding prescription criteria and medical necessity must become clearer. At the very least, there is a need to guard against obesity treatments becoming firmly established as merely 'diet shots that anyone can easily administer.'